Weight loss medications have been in the spotlight lately, and for good reason — they're changing lives. But with all the buzz around names like Mounjaro and Wegovy, it's easy to get confused. Are they the same thing? Are they safe? And how on earth do you choose?
Let's break it down — science, hormones, studies and all — so you can make an informed choice that works for your body, not against it.
GLP-1 stands for glucagon-like peptide-1 — a mouthful, we know, but stay with us. It's a hormone your body naturally produces in your gut in response to food. GLP-1 has three key jobs:
|
||
|
||
|
GLP-1 medications mimic this hormone to support appetite regulation, reduce cravings, and improve blood sugar control — all without the intense mental effort of constant willpower.
So no, it's not "just a willpower issue." These medications work on your biology, not your character.
If GLP-1 is the lead singer, glucagon and GIP (glucose-dependent insulinotropic polypeptide) are the backing vocalists that make the whole performance stronger.
|
||
|
This is where Mounjaro enters the chat.
Both are weekly injectable medications, but the hormones they target set them apart:
|
||
|
|
With Wegovy Appetite suppression, slower digestion, and better blood sugar control. |
With Mounjaro All of the above, plus enhanced fat-burning and insulin regulation thanks to the GIP effect. |
It's not about which one is "better" — it's about how your body responds.
Let's talk evidence — because we know you want more than just marketing hype.
| 13.7%Average body weight lossWegovy (semaglutide) — NEJM 2021, Wilding et al. | 20.2%Average body weight lossMounjaro (tirzepatide) — NEJM 2022, Jastreboff et al. |
Both Mounjaro and Wegovy are approved for weight management in people with a BMI of 30 or above, or 27 or above with at least one weight-related health condition.
Let's not pretend this is a one-size-fits-all decision. Here's how they compare across the questions that matter most.
| Question | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| What BMI is eligible? | BMI ≥30, or ≥27 with at least one weight-related condition (e.g. hypertension, dyslipidaemia, sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes). | BMI ≥30, or ≥27 with at least one weight-related condition (e.g. hypertension, dyslipidaemia, sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes). |
| Which causes more weight loss? | Average 20.2% body weight loss on tirzepatide in clinical trials. | Average 13.7% body weight loss on semaglutide in clinical trials. |
| Which has more side effects? | Similar GI side effects to Wegovy. Some people report stronger appetite suppression and more digestive symptoms during dose increases, but tolerance varies. | Well-established GI side effect profile. Some find it easier to tolerate. Individual response matters more than the brand itself. |
| Which suits women in perimenopause? | May be particularly useful for menopause-related weight gain, increased appetite, insulin resistance, or central weight gain. Good option where weight loss goals are higher. | A strong option for midlife weight gain, especially if appetite control is a key issue and a more established single GLP-1 medication feels preferable. |
| Which is better for appetite, cravings, or insulin resistance? | Often considered the stronger option when food noise, cravings, and insulin resistance are major drivers. Its dual GIP/GLP-1 action may offer greater metabolic benefits for some. | Very effective for appetite reduction and cravings. If insulin resistance or severe hunger are dominant issues, Mounjaro may have an edge — but Wegovy remains a strong option. |
Choosing between Mounjaro and Wegovy should always start with a proper medical assessment. The safest option depends on a number of things:
|
||
|
||
|
||
|
||
|
The best medication is not simply the strongest one. It is the one that is safest, sustainable, and appropriate for you. Always use a regulated prescriber and a licensed pharmacy — like TribElle.
We're not here to sell you a dream. We're here to back you up with:
|
|
||||
|
|
And if you're still unsure? That's okay. Your body, your timeline.
Current evidence suggests Mounjaro may be more effective for many people. In clinical studies, tirzepatide has shown greater average weight loss than semaglutide. However, "stronger" does not always mean "better" for every person. Individual response, medical history, and tolerability all matter.
Prices vary depending on the provider, dose, and supply. In the UK, Wegovy and Mounjaro are often similarly priced, though this changes regularly. It is always worth comparing regulated pharmacies and checking the full monthly treatment cost, not just the starting dose.
Both can be helpful for perimenopause-related weight gain. If appetite changes, cravings, insulin resistance, or central weight gain are major factors, Mounjaro may offer an advantage for some women. Wegovy is also highly effective and may suit those who prefer a more established single GLP-1 option. A personalised medical review is the best way to decide.
Yes. Some people switch between Mounjaro and Wegovy due to side effects, results, supply issues, or cost. Switching should always be done under prescriber guidance — dose conversion is not always direct and you may need to restart at a lower dose. We regularly support people who want to switch. Speak to a TribElle clinician to discuss your options.
Obesity is not a personal failing — it's a chronic health condition. And now, for the first time in history, we have medications that really work.
✨ You deserve access to the best evidence-based care.
✨ You deserve to feel good in your body.
✨ You deserve support that's kind, not judgmental.
That's what we're here for at TribElle.
Supporting your body during weight loss treatment can make all the difference. From vitamins to collagen support, we've got you covered.
| GLP-1 Support Pack £25 |
| Perfectil Collagen Skin £39.99 |
| Perfectil Collagen Hair £39.99 |
Sources
| Wilding et al. (2021) — Semaglutide 2.4mg for weight loss — NEJM |
| Jastreboff et al. (2022) — Tirzepatide for weight loss — NEJM |
| NICE Guidelines: Semaglutide (Wegovy) for weight management |
© TribElle Health Ltd · GPhC Registration 9012688 · tribelle.co.uk · This content is for informational purposes only. Always consult a qualified healthcare professional.